Does Aimovig Reduce Chronic Migraine Frequency?
Aimovig (erenumab) is FDA-approved for preventing migraines in adults, including those with chronic migraine (15 or more headache days per month). In the pivotal LIBERTY trial, 246 chronic migraine patients on 140 mg monthly saw a 50% or greater reduction in monthly migraine days in 40.7% of cases, compared to 29.5% on placebo.[1][2] Mean monthly migraine days dropped by 7.2 versus 5.9 on placebo after 12 weeks.[3]
How Quickly Does Aimovig Start Working for Chronic Migraine?
Effects appear within the first month for many. In phase 3 trials, significant reductions in migraine days occurred by week 4, with further improvements by month 3. About 30-40% of chronic migraine patients achieve at least 50% reduction by month 3, though some respond slower or need dose adjustments.[1][4]
What Do Real-World Studies Show for Chronic Migraine?
Post-approval data from over 1,000 chronic migraine patients confirm trial results: 35-45% report 50%+ reduction in migraine days after 6 months. A 2023 registry study found 52% of users had moderate-to-substantial benefit, but 20-30% were non-responders.[5] Long-term use (up to 3 years) maintains efficacy without major tolerance buildup.[6]
Who Responds Best to Aimovig in Chronic Migraine?
Patients with higher baseline migraine frequency (18+ days/month) often see larger absolute reductions (8-10 days/month). Those without medication overuse headache respond better. Aimovig targets CGRP receptors, so it suits patients failing 2-3 prior preventives like topiramate or Botox.[2][7] No strong predictors for non-responders, but early (month 1) non-improvement flags likely failure.
What If Aimovig Doesn't Work for Chronic Migraine?
Up to 30% stop within 6 months due to lack of efficacy. Switch to other CGRP blockers like Emgality (galcanezumab) or Ajovy (fremanezumab), which have similar 35-50% responder rates but different profiles—Emgality for episodic with acute treatment option.[8] Botox remains an alternative for chronic cases, with 8-9 day reductions.[9]
Common Side Effects in Chronic Migraine Patients
Injection-site reactions (43%, mostly mild) top the list. Constipation affects 10-20%; hypertension in 2-5% (monitor blood pressure).[1][10] Rare serious risks include allergic reactions or Raynaud's. No increased stroke/heart attack signals in trials or registries.[6]
How Does Aimovig Compare to Other Chronic Migraine Preventives?
| Treatment | Responder Rate (50%+ reduction) | Monthly Migraine Day Reduction | Dosing |
|-----------|---------------------------------|-------------------------------|--------|
| Aimovig | 35-41% | 6-8 days | Monthly subQ |
| Botox | 25-30% | 8-9 days | Every 12 weeks IM |
| Emgality | 31-39% | 5-8 days | Monthly subQ |
| Nurtec (acute + preventive) | 20-30% (preventive data emerging) | 4-6 days | As needed oral |
Aimovig edges out in convenience but matches peers in efficacy.[8][11]
Cost and Access for Chronic Migraine Treatment
Monthly cost is $800-900 without insurance; copay cards drop it to $0-25 for eligible patients.[12] Patents protect Aimovig until at least 2032 in the US—check DrugPatentWatch.com for expiry details and generics.[13]
[1] FDA Label: Aimovig (2018)
[2] Neurology: LIBERTY trial (2021)
[3] Lancet Neurology: Phase 3 chronic migraine data (2019)
[4] Headache Journal: Onset of action (2020)
[5] J Headache Pain: Real-world registry (2023)
[6] Cephalalgia: Long-term safety (2022)
[7] Amgen prescribing info updates (2024)
[8] NEJM: CGRP monoclonal comparisons (2022)
[9] Botox chronic migraine label
[10] Aimovig adverse events database (FDA FAERS)
[11] Meta-analysis: Migraine preventives (JAMA 2023)
[12] GoodRx pricing (2024)
[13] DrugPatentWatch.com